Eligibility NCT00220779 Multiple sclerosis

ODM derived from http://clinicaltrials.gov/ct2/show/NCT00220779?term=NCT00220779&rank=1

  1. StudyEvent: Eligibility
    1. Eligibility
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
Item Group
Inclusion Criteria
Age
Item
18 Years to 55 Years
boolean
Gender
Item
both
boolean
Symptoms of Multiple Sclerosis
Item
Symptoms consistent with Multiple Sclerosis up to 5 years
boolean
Diagnosis of Multiple Sclerosis
Item
Diagnosis of multiple sclerosis according to McDonald criteria.
boolean
relapsing-remitting multiple sclerosis
Item
Diagnosis of relapsing-remitting (RR) multiple sclerosis (MS) (Defined as periods of worsening of neurological function with full recovery or with sequelae and residual deficit upon recovery, periods between disease relapses characterized by lack of disease progression)
boolean
Kurtzke Extended Disability Status Scale
Item
Kurtzke Extended Disability Status Scale (EDSS) < 5.0
boolean
Contraception
Item
Females or males, females of childbearing potential must use adequate contraception
boolean
Stable Disease
Item
Clinically stable for at least 30 days prior to entry
boolean
Hyperintense lesions in the basal ganglia on MRI
Item
At least 9 hyperintense T2 lesions on MRI or 1 Gd-enhancing lesion according to McDonald/Barkhof dissemination-in-space criteria at entry
boolean
informed consent
Item
Written informed consent obtained prior to the initiation of any study related procedures
boolean
Item Group
Exclusion criteria
pregnant, breast feeding or without adequate contraception
Item
Females who are pregnant, breast feeding, or if, of childbearing potential, unwilling to practice adequate contraception throughout the study
boolean
Immunomodulatory or immunosuppressive therapy
Item
Prior therapy with azathioprine or any immunosuppressant agents within 6 months prior to study entry
boolean
steroid therapy
Item
Prior steroid, methylprednisolone or adrenocorticotropic hormone (ACTH) therapy within 30 days prior to study entry
boolean
Therapy with interferons (Betaseron(R), Avonex(R), Rebif(R)), glatiramer acetate (Copaxone(R)) or IGIV
Item
Therapy with interferons (Betaseron(R), Avonex(R), Rebif(R)), glatiramer acetate (Copaxone(R)) or IGIV within 3 months prior to study entry or during the study
boolean
Use of an investigational compound
Item
Use of an investigational compound within 6 months prior to study entry
boolean
heart diseases
Item
Cardiac insufficiency (NYHA III/IV), cardiomyopathy, significant cardiac dysrhythmia requiring treatment, unstable or advanced ischemic heart disease (CCS III or IV), or malignant hypertension
boolean
renal insufficiency
Item
History of renal insufficiency or serum creatinine levels greater than 2.5 mg/dL (221 umol/L)
boolean
IgA deficiency
Item
Known selective IgA deficiency or known antibodies to IgA
boolean
regulation of protein catabolic process
Item
Conditions whose symptoms and effects could alter protein catabolism and/or IgG utilization (e.g., protein-losing enteropathies, nephrotic syndrome)
boolean
Item Group
Medical Concepts
age
Item
age
string
C0001779 (UMLS CUI)
102518004 (SNOMED CT 2010_0731)
Gender
Item
gender
string
C0079399 (UMLS CUI)
263495000 (SNOMED CT 2010_0731)
MTHU002975 (LOINC Version 232)
diagnosis
Item
diagnosis
string
C0011900 (UMLS CUI)
439401001 (SNOMED CT 2010_0731)
MTHU008876 (LOINC Version 232)
Pharmaceutical Preparations
Item
Medication
string
C0013227 (UMLS CUI)
Multiple Sclerosis
Item
Multiple Sclerosis
string
C0026769 (UMLS CUI)
24700007 (SNOMED CT 2010_0731)
10028245 (MedDRA 13.1)
MTHU020805 (LOINC Version 232)
G35 (ICD-10-CM Version 2010)
340 (ICD-9-CM Version 2011)
Symptoms
Item
Symptoms
string
C1457887 (UMLS CUI)
MTHU021540 (LOINC Version 232)
780-789.99 (ICD-9-CM Version 2011)
Multiple Sclerosis, Relapsing-Remitting
Item
Multiple Sclerosis, Relapsing-Remitting
string
C0751967 (UMLS CUI)
426373005 (SNOMED CT 2010_0731)
10063399 (MedDRA 13.1)
Stable Disease
Item
Stable Disease
string
C0677946 (UMLS CUI)
Contraception
Item
Contraception
string
C0700589 (UMLS CUI)
146680009 (SNOMED CT 2010_0731)
10010808 (MedDRA 13.1)
Hyperintense lesions in the basal ganglia on MRI
Item
Hyperintense lesions in the basal ganglia on MRI
string
C1865351 (UMLS CUI)
Informed Consent
Item
Informed Consent
string
C0021430 (UMLS CUI)
pregnant
Item
pregnant
string
C0549206 (UMLS CUI)
10036586 (MedDRA 13.1)
Mother currently breast-feeding
Item
Mother currently breast-feeding
string
C0585066 (UMLS CUI)
169750002 (SNOMED CT 2010_0731)
Immunomodulatory or immunosuppressive therapy
Item
Immunomodulatory or immunosuppressive therapy
string
C1963758 (UMLS CUI)
86553008 (SNOMED CT 2010_0731)
10067473 (MedDRA 13.1)
corticosteroids
Item
Therapeutic Corticosteroid
string
C0001617 (UMLS CUI)
79440004 (SNOMED CT 2010_0731)
steroids
Item
steroids
string
C0038317 (UMLS CUI)
116566001 (SNOMED CT 2010_0731)
Interferons
Item
Interferons
string
C0021747 (UMLS CUI)
49327004 (SNOMED CT 2010_0731)
MTHU021353 (LOINC Version 232)
Immunoglobulins, Intravenous
Item
Immunoglobulins, Intravenous
string
C0085297 (UMLS CUI)
350344000 (SNOMED CT 2010_0731)
87 (HL7 V3 02-34)
glatiramer acetate
Item
glatiramer acetate
string
C0289884 (UMLS CUI)
108755008 (SNOMED CT 2010_0731)
Heart Diseases
Item
Cardiac disorder
string
C0018799 (UMLS CUI)
56265001 (SNOMED CT 2010_0731)
10061024 (MedDRA 13.1)
I51.9 (ICD-10-CM Version 2010)
429.9 (ICD-9-CM Version 2011)
renal insufficiency
Item
Renal Insufficiency
string
C1565489 (UMLS CUI)
10022467 (MedDRA 13.1)
Immunoglobulin A deficiency
Item
Immunoglobulin A deficiency
string
C0162538 (UMLS CUI)
29260007 (SNOMED CT 2010_0731)
10021260 (MedDRA 13.1)
regulation of protein catabolic process
Item
regulation of protein catabolic process
string
C1158003 (UMLS CUI)

Use este formulário para feedback, perguntas e sugestões de aperfeiçoamento.

Campos marcados com * são obrigatórios.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial